BioSpace News Archive

Kezar Life Sciences, Inc. announced that it entered into a collaboration and license agreement with Everest Medicines, a biopharmaceutical company focused on development, manufacturing and commercialization of innovative medicines and vaccines, to develop and commercialize zetomipzomib, Kezar’s novel, first-in-class selective immunoproteasome inhibitor, in Greater China, South Korea and Southeast Asia.

Arc Institute, the scientific research organization pioneering new models for scientific discovery and translation, is announcing the selection of its new fully funded Core Investigator and first Science Fellow, along with its first Innovation Investigators and Ignite Award Recipients.

Strykagen Corp. announced today that it was awarded a $958,973 (of a total $1,953,245) Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH) to conduct Investigational New Drug (IND) enabling studies for S-969, a first-in-class small molecule that may halt or reverse muscle wasting diseases, like muscular dystrophies, cachexia and sarcopenia.

Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will participate in the Cantor Fitzgerald Global Healthcare Conference 2023 taking place September 26 - 28 in New York City.

The Curiosity Cube, a 22x10-foot shipping container turned mobile science lab from MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has been hard at work sparking kids’ interest in STEM careers on its fifth annual U.S tour.

Inventiva (Euronext Paris and Nasdaq: IVA), and Hepalys Pharma, Inc. have entered into an exclusive licensing agreement (the “Agreement”) to develop and commercialize Inventiva’s proprietary drug candidate lanifibranor for the treatment of non-alcoholic steatohepatitis (NASH) in Japan and South Korea.

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that updated Phase 1 clinical data from its ongoing Phase 1/2 PYNNACLE study of PC14586 will be presented in a late-breaking poster session at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

Zebrafish have revolutionized research into a wide variety of rare and complex genetic diseases.

GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced its first half-year 2023 financial results and provided a corporate update.

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the “Company” or “Anebulo”), today announced financial results for the three and twelve months ended June 30, 2023, and recent updates.